The Concise Guide to PHARMACOLOGY 2013/14: overview. by Alexander, SP et al.
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14:
OVERVIEW
Stephen P.H. Alexander*1, Helen E. Benson2, Elena Faccenda2, Adam J. Pawson2,
Joanna L. Sharman2, John C. McGrath3, William A. Catterall6, Michael Spedding4, John A. Peters5,
Anthony J. Harmar2 and CGTP Collaborators
*Author for correspondence; steve.alexander@guidetopharmacology.org
1School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK
2The University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4TJ, UK
3School of Life Science, University of Glasgow, Glasgow G12 8QQ, UK
4Spedding Research Solutions SARL, Le Vésinet 78110, France
5Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
6Department of Pharmacology, School of Medicine, University of Washington, Seattle, WA 98195-7280, USA
Abstract
The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties from the IUPHAR database. The full contents can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full.
This compilation of the major pharmacological targets is divided into seven areas of focus: G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone
receptors, transporters and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions
for further reading. A new landscape format has easy to use tables comparing related targets.
It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in previous Guides to Receptors & Channels. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate.
It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates.
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An Introduction to the Concise Guide to PHARMACOLOGY 2013/14
The great proliferation of drug targets in recent years has driven
the need to provide a logically-organised synopsis of the nomen-
clature and pharmacology of these targets. This is the underlying
reason for this Guide to PHARMACOLOGY 2013/14, distributed
with the British Journal of Pharmacology, and produced in asso-
ciation with NC-IUPHAR, the Nomenclature Committees of the
International Union of Basic and Clinical Pharmacology. Our
intent is to produce an authoritative but user-friendly publica-
tion, which allows a rapid overview of the key properties of a
wide range of established or potential pharmacological targets.
The aim is to provide information succinctly, so that a newcomer
to a particular target group can identify the main elements ‘at a
glance’. It is not our goal to produce all-inclusive reviews of the
targets presented; references to these are included in the Further
Reading sections of the entries or, for many targets, the website
www.guidetopharmacology.org provides access to more exten-
sive information. The Guide to PHARMACOLOGY 2013/14 pre-
sents each entry, typically a circumscribed target class family on,
wherever possible, a single page, so as to allow easy access and
rapid oversight.
The list of targets present is, in many cases, a comprehensive
reflection of the known targets within the particular group. Our
philosophy has been to present data on human proteins wherever
possible, both in terms of structural information and pharmacol-
ogy. To this end, the HGNC gene nomenclature and UniProt
unique ID are indicated to allow rapid access through free online
databases for further information. In a few cases, where structural
or pharmacological information is not available for human
targets, we have used data from other species, as indicated. A
priority in constructing these tables was to present agents which
represent the most selective and which are available by donation
or from commercial sources, now or in the near future.
The Guide is divided into seven further sections, which comprise
pharmacological targets of similar structure/function. These are
G protein-coupled receptors, ligand-gated ion channels, ion
channels, catalytic receptors, nuclear hormone receptors, trans-
porters and enzymes. In this overview are listed protein targets
of pharmacological interest, which are not G protein-coupled
receptors, ligand-gated ion channels, ion channels, nuclear
hormone receptors, catalytic receptors, transporters or enzymes.
In comparison with the Fifth Edition of the Guide to Receptors &
Channels [1], we have added a number of new records, expand-
ing the total to include over 2000 protein targets, primarily from
increasing the content on transporters and enzymes.
The Editors of the Guide have compiled the individual records,
taking advice from many Collaborators (listed on page 1452).
Where appropriate, an indication is given of the status of the
nomenclature, as proposed by NC-IUPHAR, published in Phar-
macological Reviews. Where this guidance is lacking, advice from
several prominent, independent experts has generally been
obtained to produce an authoritative consensus, which attempts
to fit in within the general guidelines from NC-IUPHAR [2].
Tabulated data provide ready comparison of selective agents and
probes (radioligands and PET ligands, where available) within a
family of targets and additional commentary highlights whether
species differences or ligand metabolism are potential confound-
ing factors. We recommend that any citations to information in
the Concise Guide are presented in the following format:
Alexander SPH et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14. Br J Pharmacol 170: 1449–1867.
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Adiponectin receptors
Overview: Adiponectin receptors (provisional nomenclature,
ENSFM00500000270960) respond to the 30 kDa complement-
related protein hormone adiponectin (also known as ADIPOQ:
adipocyte, C1q and collagen domain-containing protein;
ACRP30, adipose most abundant gene transcript 1; apM-1;
gelatin-binding protein: Q15848) originally cloned from adipo-
cytes [4]. Although sequence data suggest 7TM domains,
immunological evidence indicates that, contrary to typical 7TM
topology, the carboxyl terminus is extracellular, while the amino
terminus is intracellular [6]. Signalling through these receptors
appears to avoid G proteins. Adiponectin receptors appear rather
to stimulate protein phosphorylation via AMP-activated protein
kinase and MAP kinase pathways [6], possibly through the
protein partner APPL1 (adaptor protein, phosphotyrosine
interaction, PH domain and leucine zipper containing 1,
Q9UKG1 [5]). The adiponectin receptors are a class of proteins
(along with membrane progestin receptors), which contain seven
sequences of aliphatic amino acids reminiscent of GPCRs, but
which are structurally and functionally distinct from that class of
receptor.
Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin > adiponectin globular adiponectin = adiponectin
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [3].
Further reading
Buechler C, Wanninger J, Neumeier M. (2010) Adiponectin receptor binding proteins–recent
advances in elucidating adiponectin signalling pathways. FEBS Lett 584: 4280–4286.
[PMID:20875820]
Dalamaga M, Diakopoulos KN, Mantzoros CS. (2012) The role of adiponectin in cancer: a review of
current evidence. Endocr Rev 33: 547–594. [PMID:22547160]
Goldstein BJ, Scalia RG, Ma XL. (2009) Protective vascular and myocardial effects of adiponectin.
Nat Clin Pract Cardiovasc Med 6: 27–35. [PMID:19029992]
Juhl C, Beck-Sickinger AG. (2012) Molecular tools to characterize adiponectin activity. Vitam Horm
90: 31–56. [PMID:23017711]
Shetty S, Kusminski CM, Scherer PE. (2009) Adiponectin in health and disease: evaluation of
adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30: 234–239.
[PMID:19359049]
Sun Y, Xun K, Wang C, Zhao H, Bi H, Chen X, Wang Y. (2009) Adiponectin, an unlocking
adipocytokine. Cardiovasc Ther 27: 59–75. [PMID:19207481]
Thundyil J, Pavlovski D, Sobey CG, Arumugam TV. (2012) Adiponectin receptor signalling in the
brain. Br J Pharmacol 165: 313–327. [PMID:21718299]
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Fatty acid binding proteins
Overview: Fatty acid-binding proteins are low molecular weight
(100–130 aa) chaperones for long chain fatty acids, fatty acyl
CoA esters, eicosanoids, retinols, retinoic acids and related
metabolites and are usually regarded as being responsible for
allowing the otherwise hydrophobic ligands to be mobile in
aqueous media. These binding proteins may perform functions
extracellularly (e.g. in plasma) or transport these agents; to the
nucleus to interact with nuclear receptors (principally PPARs and
retinoic acid receptors [16]) or for interaction with metabolic
enzymes. Although sequence homology is limited, crystallo-
graphic studies suggest conserved 3D structures across the group
of binding proteins.
Preferred abbreviation FABP1 FABP2 FABP3 FABP4 FABP5
Nomenclature fatty acid binding protein 1, liver fatty acid binding protein 2,
intestinal
fatty acid binding protein 3,
muscle and heart (mammary-
derived growth inhibitor)
fatty acid binding protein 4,
adipocyte
fatty acid binding
protein 5 (psoriasis-associated)
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090 FABP5, Q01469
Rank order of
potency
stearic acid, oleic acid > palmitic
acid, linoleic acid > arachidonic
acid, α-linolenic acid [13]
stearic acid > palmitic acid,oleic
acid > linoleic acid > arachidonic
acid, α-linolenic acid [13]
stearic acid, oleic acid, palmitic
acid > linoleic acid, α-linolenic
acid, arachidonic acid [13]
oleic acid, palmitic acid, stearic
acid, linoleic acid > α-linolenic
acid, arachidonic acid [13]
–
Comment A broader substrate specificity
than other FABPs, binding two
fatty acids per protein [18]
Crystal structure of the rat
FABP2 [15]
Crystal structure of the human
FABP3 [19]
– Crystal structure of the human
FABP5 [11]
Preferred abbreviation FABP6 FABP7 FABP8 FABP9 FABP12
Nomenclature fatty acid binding protein 6,
ileal
fatty acid binding protein 7,
brain
peripheral myelin
protein 2
fatty acid binding protein 9,
testis
fatty acid binding protein 12
HGNC, UniProt FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comment Able to transport bile acids [20] Crystal structure of the human
FABP7 [7]
In silico modelling suggests that
FABP8 can bind both fatty acids
and cholesterol [12]
– –
Preferred abbreviation RBP1 RBP2 RBP3 RBP4 RBP5
Nomenclature retinol binding protein 1,
cellular
retinol binding protein 2,
cellular
retinol binding protein 3,
interstitial
retinol binding protein 4,
plasma
retinol binding protein 5,
cellular
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980
Rank order of
potency
– stearic acid > palmitic acid,
oleic acid, linoleic acid,
α-linolenic acid, arachidonic
acid [14]
– – –
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Preferred abbreviation RBP7 RLBP1 CRABP1 CRABP2
Nomenclature retinol binding protein 7, cellular retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RBP7, Q96R05 RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of potency – 11-cis-retinal, 11-cis-retinol > 9-cis-retinal,
13-cis-retinal, 13-cis-retinol,
all-trans-retinal, retinol [8]
all-trans-retinoic acid > 9-cis-retinoic acid
stearic acid > palmitic acid, oleic acid,
linoleic acid, α-linolenic acid, arachidonic
acid [14]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high affinity for FABP4 (pIC50 ∼8.8) compared to FABP3 or FABP5 (pIC50 <6.6, [9,17]). HTS01037 is reported to interfere with FABP4 action
[10]. Multiple pseudogenes for the FABPs have been identified in the human genome.
Further reading
Chmurzyn´ska A. (2006) The multigene family of fatty acid-binding proteins (FABPs): function,
structure and polymorphism. J Appl Genet 47: 39–48. [PMID:16424607]
Furuhashi M, Hotamisligil GS. (2008) Fatty acid-binding proteins: role in metabolic diseases and
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Sigma receptors
Overview: Although termed ‘receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been observed to
bind to these sites, which appear to be intracellular.
Nomenclature σ1 (sigma non-opioid intracellular receptor 1) σ2
HGNC, UniProt SIGMAR1, Q99720 –
Selective agonists (+)-SK&F10047, (RS)-PPCC (pKi 8.8) [25], PRE-084 (pIC50 7.4) [26] PB-28 (pKi 8.3) [21]
Selective antagonists NE-100 (pIC50 8.4) [24], BD-1047 (pIC50 7.4) [23] (RS)-SM21 (pIC50 7.2) [22]
Radioligands (Kd) [3H]-pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments: (-)-pentazocine also shows activity at opioid receptors. There is no molecular correlate of the sigma2 receptor.
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